Black Swan Analysis and ICCI collaborate to provide commercial insights to companies developing medical cannabis and cannabinoid treatments
The International Cannabis and Cannabinoids Institute (ICCI) and Black Swan Analysis executed an Exclusive Collaboration Agreement to provide commercial insights and indication-specific market analysis to help the advancement of cannabis and cannabinoid treatments for patients for whom there is no effective treatment available.
Long-term debilitating health conditions such as multiple sclerosis, dementia, chronic pain and difficult to treat forms of epilepsy leave hundreds of thousands of patients worldwide without effective treatment or in some cases any treatment at all to alleviate the symptoms of their conditions.
ICCI’s Chief Executive Officer, Pavel Kubů said “Being able to provide companies developing medical cannabis treatments with better data will be a significant benefit to identify and prioritize patient groups with significant unmet need. This will also drive investment which will help accelerate the development of these much-needed therapies.”
“It’s very exciting for us to be partnering with the ICCI. We’re looking forward to working on some interesting projects under this collaboration and help get therapies to patients that need them” said Nic Talbot-Watt, CEO and founder of Black Swan Analysis.
About Black Swan Analysis
Black Swan Analysis Ltd is a London-based consultancy specializing in asset valuations and epidemiology. They have a global client base which includes Top 25 pharma companies as well as biotech and tech transfer offices.
International Cannabis and Cannabinoids Institute (ICCI) is the first Center of Excellence in the field of medical cannabis and cannabinoid treatment located in the heart of Europe - Czech Republic. ICCI identifies, coordinates and supports global research priorities for the advancement of cannabis and cannabinoid treatments through a multidisciplinary, evidence-based approach that incorporates innovative tools and methods.